Cargando…
Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2)
Although insulin resistance consistently occurs with type 1 diabetes, its predominant driver is uncertain. We therefore determined the relative contributions of hyperglycemia and iatrogenic hyperinsulinemia to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant groups (n...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692813/ https://www.ncbi.nlm.nih.gov/pubmed/31092478 http://dx.doi.org/10.2337/db19-0324 |
_version_ | 1783443609718095872 |
---|---|
author | Gregory, Justin M. Smith, T. Jordan Slaughter, James C. Mason, Holly R. Hughey, Curtis C. Smith, Marta S. Kandasamy, Balamurugan Greeley, Siri Atma W. Philipson, Louis H. Naylor, Rochelle N. Letourneau, Lisa R. Abumrad, Naji N. Cherrington, Alan D. Moore, Daniel J. |
author_facet | Gregory, Justin M. Smith, T. Jordan Slaughter, James C. Mason, Holly R. Hughey, Curtis C. Smith, Marta S. Kandasamy, Balamurugan Greeley, Siri Atma W. Philipson, Louis H. Naylor, Rochelle N. Letourneau, Lisa R. Abumrad, Naji N. Cherrington, Alan D. Moore, Daniel J. |
author_sort | Gregory, Justin M. |
collection | PubMed |
description | Although insulin resistance consistently occurs with type 1 diabetes, its predominant driver is uncertain. We therefore determined the relative contributions of hyperglycemia and iatrogenic hyperinsulinemia to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant groups (n = 10/group) with differing insulinemia and glycemia: healthy control subjects (euinsulinemia and euglycemia), glucokinase–maturity-onset diabetes of the young (GCK-MODY; euinsulinemia and hyperglycemia), and type 1 diabetes (hyperinsulinemia and hyperglycemia matching GCK-MODY). We assessed the contribution of hyperglycemia by comparing insulin sensitivity in control and GCK-MODY and the contribution of hyperinsulinemia by comparing GCK-MODY and type 1 diabetes. Hemoglobin A(1c) was normal in control subjects and similarly elevated for type 1 diabetes and GCK-MODY. Basal insulin levels in control subjects and GCK-MODY were nearly equal but were 2.5-fold higher in type 1 diabetes. Low-dose insulin infusion suppressed endogenous glucose production similarly in all groups and suppressed nonesterified fatty acids similarly between control subjects and GCK-MODY, but to a lesser extent for type 1 diabetes. High-dose insulin infusion stimulated glucose disposal similarly in control subjects and GCK-MODY but was 29% and 22% less effective in type 1 diabetes, respectively. Multivariable linear regression showed that insulinemia—but not glycemia—was significantly associated with muscle insulin sensitivity. These data suggest that iatrogenic hyperinsulinemia predominates in driving insulin resistance in type 1 diabetes. |
format | Online Article Text |
id | pubmed-6692813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-66928132020-08-01 Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) Gregory, Justin M. Smith, T. Jordan Slaughter, James C. Mason, Holly R. Hughey, Curtis C. Smith, Marta S. Kandasamy, Balamurugan Greeley, Siri Atma W. Philipson, Louis H. Naylor, Rochelle N. Letourneau, Lisa R. Abumrad, Naji N. Cherrington, Alan D. Moore, Daniel J. Diabetes Metabolism Although insulin resistance consistently occurs with type 1 diabetes, its predominant driver is uncertain. We therefore determined the relative contributions of hyperglycemia and iatrogenic hyperinsulinemia to insulin resistance using hyperinsulinemic-euglycemic clamps in three participant groups (n = 10/group) with differing insulinemia and glycemia: healthy control subjects (euinsulinemia and euglycemia), glucokinase–maturity-onset diabetes of the young (GCK-MODY; euinsulinemia and hyperglycemia), and type 1 diabetes (hyperinsulinemia and hyperglycemia matching GCK-MODY). We assessed the contribution of hyperglycemia by comparing insulin sensitivity in control and GCK-MODY and the contribution of hyperinsulinemia by comparing GCK-MODY and type 1 diabetes. Hemoglobin A(1c) was normal in control subjects and similarly elevated for type 1 diabetes and GCK-MODY. Basal insulin levels in control subjects and GCK-MODY were nearly equal but were 2.5-fold higher in type 1 diabetes. Low-dose insulin infusion suppressed endogenous glucose production similarly in all groups and suppressed nonesterified fatty acids similarly between control subjects and GCK-MODY, but to a lesser extent for type 1 diabetes. High-dose insulin infusion stimulated glucose disposal similarly in control subjects and GCK-MODY but was 29% and 22% less effective in type 1 diabetes, respectively. Multivariable linear regression showed that insulinemia—but not glycemia—was significantly associated with muscle insulin sensitivity. These data suggest that iatrogenic hyperinsulinemia predominates in driving insulin resistance in type 1 diabetes. American Diabetes Association 2019-08 2019-05-15 /pmc/articles/PMC6692813/ /pubmed/31092478 http://dx.doi.org/10.2337/db19-0324 Text en © 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
spellingShingle | Metabolism Gregory, Justin M. Smith, T. Jordan Slaughter, James C. Mason, Holly R. Hughey, Curtis C. Smith, Marta S. Kandasamy, Balamurugan Greeley, Siri Atma W. Philipson, Louis H. Naylor, Rochelle N. Letourneau, Lisa R. Abumrad, Naji N. Cherrington, Alan D. Moore, Daniel J. Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) |
title | Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) |
title_full | Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) |
title_fullStr | Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) |
title_full_unstemmed | Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) |
title_short | Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2) |
title_sort | iatrogenic hyperinsulinemia, not hyperglycemia, drives insulin resistance in type 1 diabetes as revealed by comparison with gck-mody (mody2) |
topic | Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692813/ https://www.ncbi.nlm.nih.gov/pubmed/31092478 http://dx.doi.org/10.2337/db19-0324 |
work_keys_str_mv | AT gregoryjustinm iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT smithtjordan iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT slaughterjamesc iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT masonhollyr iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT hugheycurtisc iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT smithmartas iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT kandasamybalamurugan iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT greeleysiriatmaw iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT philipsonlouish iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT naylorrochellen iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT letourneaulisar iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT abumradnajin iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT cherringtonaland iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 AT mooredanielj iatrogenichyperinsulinemianothyperglycemiadrivesinsulinresistanceintype1diabetesasrevealedbycomparisonwithgckmodymody2 |